News /
min read /
February 3, 2022

Gabriela Perez Joins Big Health as Chief Commercial Officer


After spending two decades successfully scaling multiple healthcare technology companies, Perez joins Big Health to accelerate the commercial coverage and reimbursement for digital therapeutics

SAN FRANCISCO, February 3, 2022 — Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced the appointment of Gabriela Perez as Chief Commercial Officer. In her new role, Perez will oversee Big Health’s global commercial growth and strategy, including sales, client management, strategic partnerships, and new markets.

Perez has spent the past two decades building and scaling several technology-enabled health care services companies. Most recently, she was Executive Vice President & General Manager at Ovia Health, the largest women & family digital health company in the United States, where she led the company to triple digit year-over-year revenue growth while overseeing more than 2,000 clients, and signing 27 new regional and national health plan partnerships. Ovia Health was acquired by Labcorp (NYSE: LH) in August 2021.

Her entrepreneurial career began as part of the founding team of Best Doctors, a telehealth company that pioneered e-second opinions globally. During her tenure at Best Doctors, Perez held multiple leadership positions across product, marketing, partnerships, and global sales divisions. She was responsible for scaling business units across 45 countries, accounting for hundreds of millions of dollars in revenue. Best Doctors was acquired by Teladoc Health (NYSE: TDOC) in June 2017.

“Over the past two decades, Gabriela has proven her exceptional ability to drive rapid growth for innovative healthcare companies,” said Big Health Co-Founder and CEO Peter Hames. “But what sets Gabriela apart is her humility and mission-driven mentality. This unique combination makes her a perfect fit for Big Health, and we cannot be more excited to welcome her to the team as we continue to accelerate our growth in pursuit of helping millions back to good mental health.”

Big Health is the most scaled digital therapeutics company with the most studied products, including over 10 million covered lives globally, 13 randomized controlled trials evaluating its approach, and more than 28,000 participants across all clinical evidence studies. Sleepio and Daylight¹, Big Health’s digital therapeutics for insomnia and anxiety, offer fully automated products that deliver evidence-based mental health care, including cognitive behavioral therapy, without intervention from coaches or clinicians. Through robust clinical evaluation, Big Health’s digital therapeutics are proven first-line treatments for mental health care.

“Over the course of my career in healthcare technology, I have identified three key trends that are paramount to the success of a business: focus on clinical and evidence-based care, purposeful design and engagement, and innovative commercial models,” said Perez. “Big Health is leading the digital therapeutics industry in all three areas, and is poised for even faster growth ahead. I cannot be more excited to join Peter and the entire Big Health team to advance our mission of helping millions back to good mental health.”

This key addition follows two momentous announcements for Big Health. In January 2022, Big Health announced a $75 million Series C funding, led by SoftBank Vision Fund 2. The company also announced that it added former Food and Drug Administration (FDA) Deputy Commissioner for Medical and Scientific Affairs Dr. Anand Shah to its Board of Directors to bolster the company’s clinical and public policy strategies.

About Big Health

Big Health’s mission is to help millions back to good mental health by providing safe and effective non-drug alternatives for the most common mental health conditions including insomnia and anxiety. Designed by leading clinical experts, Big Health’s digital therapeutics expand access to gold standard care, including behavioral medicine, and are backed by industry-leading research and randomized controlled trials. By seamlessly integrating across the care pathway, from member engagement to billing via pharmacy benefit managers, Big Health simplifies adoption for both payers and patients, providing an inclusive, scalable, and affordable approach without serious side effects. For more information, please visit or follow Big Health on LinkedIn and Twitter.

Big Health Media Contact:

Jake Mazanke


In accordance with FDA’s Current Enforcement Discretion Policy for Digital Health Devices for Psychiatric Disorders, for patients aged 18 years and older, who are followed by and diagnosed with Insomnia Disorder or Generalized Anxiety Disorder by a medical provider, Sleepio and Daylight can be made available as an adjunct to their usual medical care for Insomnia Disorder or Generalized Anxiety Disorder, respectively. Sleepio and Daylight do not replace the care of a medical provider or the patient’s medication. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for these indications.

Disclaimer: In the UK, Sleepio and Daylight are CE marked medical devices available for the treatment of insomnia disorder and generalized anxiety disorder, respectively

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023